| abstract |
The present invention discloses sulfonamide CA IX-selective inhibitors, which selectively bind to the enzyme under hypoxic conditions and are able to reverse the tumor acidification mediated by the enzyme. These compounds are useful in anticancer therapies based on tumor-associated CA isozyme inhibition as well as for hypoxic tumor imaging. The inhibitors contain a fluorescent moiety, preferably fluorescein. |